Capital International Sarl Has $2.72 Million Holdings in Novo Nordisk A/S (NYSE:NVO)

Capital International Sarl boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 2.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,634 shares of the company’s stock after acquiring an additional 809 shares during the period. Capital International Sarl’s holdings in Novo Nordisk A/S were worth $2,721,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. GQG Partners LLC boosted its stake in Novo Nordisk A/S by 74.7% during the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company’s stock valued at $1,117,790,000 after purchasing an additional 5,556,460 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $404,910,000. Loomis Sayles & Co. L P grew its stake in shares of Novo Nordisk A/S by 34.2% in the fourth quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company’s stock worth $995,397,000 after acquiring an additional 2,947,771 shares during the last quarter. Clearbridge Investments LLC increased its position in Novo Nordisk A/S by 59.8% during the fourth quarter. Clearbridge Investments LLC now owns 4,283,317 shares of the company’s stock worth $368,451,000 after acquiring an additional 1,602,549 shares during the period. Finally, Sustainable Growth Advisers LP raised its stake in Novo Nordisk A/S by 23.6% during the 4th quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company’s stock valued at $459,416,000 after purchasing an additional 1,021,498 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BMO Capital Markets restated a “market perform” rating and issued a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday. They set an “underperform” rating on the stock. Finally, Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Hold” and a consensus price target of $135.00.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $57.99 on Friday. The stock has a market capitalization of $260.23 billion, a price-to-earnings ratio of 17.63, a P/E/G ratio of 0.90 and a beta of 0.61. The firm’s 50-day moving average price is $75.52 and its two-hundred day moving average price is $91.71. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 1-year low of $57.28 and a 1-year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st were issued a dividend of $0.7874 per share. The ex-dividend date was Monday, March 31st. This represents a yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio is currently 49.54%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.